Muse bio Completes $23m Series B Financing

musebioMuse bio, a Boulder, CO-based developer of genome engineering capabilities, completed a $23m Series B financing.

The round was led by Venrock with participation from Foresite Capital and Paladin Capital as well as existing investors NanoDimension and Spruce/MLS.

The company intends to use the funds to accelerate its development efforts to bring its ForgeCraft™ to scientists worldwide.

Led by Kevin Ness, CEO, Muse bio is advancing genome engineering and synthetic biology technology (ForgeCraft) which combines computer aided forward design software package, a proprietary benchtop biofoundry, and custom reagents to enable researchers and production scientists to rapidly explorate the genetic landscape at scale and accelerate their work.



Join the discussion